Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161116 · ClinicalTrials.gov registry record · Phase 2
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT06161116 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 149 participants.
The verdict
NCT06161116, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MK-6194
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161116
The ClinicalTrials.gov registry entry for NCT06161116 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06161116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06161116 about?
NCT06161116 is a clinical study titled "Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)". The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythema...
What is the current status of trial NCT06161116?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2023-12-27. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06161116?
The interventions under investigation include: Placebo (BIOLOGICAL), MK-6194 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06161116?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.